WO2001076606A3 - Use of uric acid or precursors thereof as a treatment for cancer, aids and the like - Google Patents

Use of uric acid or precursors thereof as a treatment for cancer, aids and the like Download PDF

Info

Publication number
WO2001076606A3
WO2001076606A3 PCT/CA2001/000457 CA0100457W WO0176606A3 WO 2001076606 A3 WO2001076606 A3 WO 2001076606A3 CA 0100457 W CA0100457 W CA 0100457W WO 0176606 A3 WO0176606 A3 WO 0176606A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
uric acid
aids
cancer
precursors
Prior art date
Application number
PCT/CA2001/000457
Other languages
French (fr)
Other versions
WO2001076606A2 (en
Inventor
Roman Rozencwaig
Original Assignee
Roman Rozencwaig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roman Rozencwaig filed Critical Roman Rozencwaig
Priority to AU2001248173A priority Critical patent/AU2001248173A1/en
Priority to CA002405591A priority patent/CA2405591A1/en
Publication of WO2001076606A2 publication Critical patent/WO2001076606A2/en
Publication of WO2001076606A3 publication Critical patent/WO2001076606A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

Treatment or prevention of cancer, AIDS, infectious diseases, viral diseases, premature aging, depression, weakening of the immune system in a mammal by raising the level of uric acid in a person to about 300 to 500 νmol/l. Kit to monitor the levels of uric acid in a mammal requiring such treatment or liable to suffer from the above diseases is also disclosed.
PCT/CA2001/000457 2000-04-07 2001-04-04 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like WO2001076606A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001248173A AU2001248173A1 (en) 2000-04-07 2001-04-04 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
CA002405591A CA2405591A1 (en) 2000-04-07 2001-04-04 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,304,869 2000-04-07
CA002304869A CA2304869A1 (en) 2000-04-07 2000-04-07 Method of medical treatment using uric acid or precursors thereof

Publications (2)

Publication Number Publication Date
WO2001076606A2 WO2001076606A2 (en) 2001-10-18
WO2001076606A3 true WO2001076606A3 (en) 2002-08-01

Family

ID=4165836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/000457 WO2001076606A2 (en) 2000-04-07 2001-04-04 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like

Country Status (3)

Country Link
AU (1) AU2001248173A1 (en)
CA (1) CA2304869A1 (en)
WO (1) WO2001076606A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
WO1997039352A1 (en) * 1996-04-15 1997-10-23 Fox Chase Cancer Center Assays for detection of purine metabolites
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
WO2000006171A1 (en) * 1998-07-31 2000-02-10 Hme Enterprises, Llc Antioxidant composition and method of treating diseases using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
WO1997039352A1 (en) * 1996-04-15 1997-10-23 Fox Chase Cancer Center Assays for detection of purine metabolites
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
WO2000006171A1 (en) * 1998-07-31 2000-02-10 Hme Enterprises, Llc Antioxidant composition and method of treating diseases using same

Also Published As

Publication number Publication date
WO2001076606A2 (en) 2001-10-18
CA2304869A1 (en) 2001-10-07
AU2001248173A1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
AU2001210604A1 (en) Genotyping kit for diagnosis of human papillomavirus infection
WO2003020889A3 (en) Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
EP1390472A4 (en) Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
WO2001089457A3 (en) Thrombopoietin mimetics
WO2004054581A3 (en) Cyclohexyl compounds as ccr5 antagonists
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
WO2004103407A3 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
EP1790728A3 (en) Imaging, diagnosis and treatment of disease
AU2002331313A1 (en) Use of l-polynucleotides and derivatives thereof for in vivo imaging
ZA200303760B (en) Use of polymers as filtering aids and/or stabilizers.
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
CA2014885A1 (en) 6,11-dihydro-5h-pyrido[2,3-b][1,5]benzodiazepin-5-ones and thiones and their use in the prevention or treatment of aids
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
WO2001076606A3 (en) Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
BG104368A (en) Novel polymorphic forms of cipamfylline
WO2001096397A3 (en) Cd154 variants and uses thereof
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003059262A3 (en) Method and composition for treating and preventing hiv infection and aids
WO2002044328A3 (en) Anti-angiogenic polypeptides
WO2002046214A3 (en) Immunomodulatory protein derived from the yaba monkey tumor virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2405591

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP